Duobrii (Halobetasol propionate/Tazarotene) for Psoriasis

Overview
Duobrii is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat plaque psoriasis in people ages 18 and older. Duobrii is a combination drug composed of halobetasol propionate and tazarotene.

Halcinonide propionate is a high-potency corticosteroid. It is believed that halcinonide propionate works in cases of psoriasis by suppressing immune system activity. Tazarotene is an acetylenic retinoid. Retinoids are chemicals that are related to vitamin A. It is believed that tazarotene works in cases of psoriasis by regulating skin cell growth.

How do I take it?
Duobrii is applied topically to the affected areas in the form of a lotion.

Side effects
The FDA-approved label for Duobrii lists common side effects including redness, itching, swelling, burning, stinging, pain at the application site, inflamed hair follicles, thinning of the skin, peeling, and rash.

Rare but serious side effects listed for Duobrii include hyperglycemia (high blood sugar), a raised risk for sunburn, and vision problems including an increased chance of developing cataracts and glaucoma. Duobrii can cause problems with metabolism such as the development of Cushing syndrome and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression.

For more details about this treatment, visit:

Duobrii — Ortho Dermatologics
https://www.duobrii.com